Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs TG Therapeutics Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $64.78, while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $59.06 |
52-Week Low | $43.88 | $26.94 |
Market Cap | — | $7.58B |
Enterprise Value | — | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.77, up 0.9% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF focuses on AI and technology stocks, benefiting from sector momentum, though key valuation ratios like P/E and P/S are not provided in the data. Recent news highlights AI's growth potential but also warns of market euphoria and valuation concerns.
The outlook for AIQ is positive due to AI sector tailwinds, but risks include high valuations and economic sensitivity. Investment opportunity lies in diversified AI exposure, while caution is warranted from overbought technicals and potential sector volatility.
TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.
The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
